Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioHarvest Sciences ( (BHST) ) has shared an update.
On March 13, 2026, BioHarvest Sciences announced that its board approved long-term equity incentive awards for employees, officers and directors under the company’s equity plan. The package comprises 516,812 stock options and 264,121 restricted share units, all priced at the March 13 closing share value, with a ten-year option term and quarterly vesting over three years starting on that date.
Management framed the move as a way to align staff with shareholders, reward past performance, and support retention while conserving cash resources. The company tied the incentives to its broader strategy of scaling its Botanical Synthesis platform across nutraceutical products and CDMO services, underscoring that securing and keeping top scientific and commercial talent is central to sustaining growth and long-term shareholder returns.
The most recent analyst rating on (BHST) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
The score is held down primarily by weak financial performance (ongoing net losses, negative operating/free cash flow, and elevated leverage) and bearish technicals (below key moving averages with negative MACD). The latest earnings call adds support via strong revenue growth, improving gross margins, and guidance pointing toward adjusted EBITDA breakeven, but valuation remains constrained by unprofitability and no dividend.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company listed on NASDAQ and Frankfurt that specializes in Botanical Synthesis, a patented platform for producing plant-based compounds without growing the whole plant. It operates two main verticals: a CDMO business developing novel plant-derived compounds for clients and a proprietary nutraceutical line focused on science-backed dietary supplements and wellness products.
Average Trading Volume: 32,376
Technical Sentiment Signal: Buy
Current Market Cap: $94.02M
For detailed information about BHST stock, go to TipRanks’ Stock Analysis page.